Three Companies Priced Below Estimated Value In May 2026
Corcept Therapeutics Incorporated. CORT | 0.00 |
In the last week, the market has stayed flat, yet it is up 24% over the past year with earnings forecasted to grow by 17% annually. In such a vibrant market environment, identifying undervalued stocks can provide investors with opportunities to capitalize on potential growth at a discounted price.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Upstart Holdings (UPST) | $29.51 | $57.94 | 49.1% |
| Travere Therapeutics (TVTX) | $42.59 | $84.14 | 49.4% |
| MercadoLibre (MELI) | $1546.81 | $3025.20 | 48.9% |
| Lazard (LAZ) | $45.23 | $89.09 | 49.2% |
| Kaspi.kz (KSPI) | $87.51 | $173.56 | 49.6% |
| FB Financial (FBK) | $51.30 | $101.61 | 49.5% |
| CVR Energy (CVI) | $33.89 | $67.53 | 49.8% |
| Coastal Financial (CCB) | $68.41 | $134.79 | 49.2% |
| Beazer Homes USA (BZH) | $22.12 | $43.29 | 48.9% |
| AbbVie (ABBV) | $210.39 | $420.32 | 49.9% |
Let's take a closer look at a couple of our picks from the screened companies.
Corcept Therapeutics (CORT)
Overview: Corcept Therapeutics Incorporated is a biopharmaceutical company focused on developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States, with a market cap of $6.05 billion.
Operations: The company generates its revenue primarily from the discovery, development, and commercialization of pharmaceutical products, amounting to $769.10 million.
Estimated Discount To Fair Value: 32.6%
Corcept Therapeutics is trading at US$56.37, significantly below its estimated cash flow value of US$83.61, suggesting undervaluation based on discounted cash flows. Despite reporting a Q1 net loss of US$31.76 million, Corcept raised its 2026 revenue guidance to between $950 million and $1,050 million. The company's earnings are forecast to grow significantly over the next three years, outpacing market averages despite recent legal challenges and mixed trial results in their drug pipeline.
Mama's Creations (MAMA)
Overview: Mama's Creations, Inc., along with its subsidiaries, manufactures and markets fresh deli-prepared foods in the United States and has a market cap of approximately $587.49 million.
Operations: The company's revenue is primarily derived from its food processing segment, which amounts to $171.71 million.
Estimated Discount To Fair Value: 20.8%
Mama's Creations, trading at US$14.45, is undervalued based on its discounted cash flow value of US$18.24. With earnings forecast to grow 40.3% annually, surpassing the US market average of 16.8%, and recent revenue growth from US$123.33 million to US$171.71 million, the company shows strong potential for future profitability. The expansion into Walmart and Target locations enhances its national footprint, complementing its strategy for sustained growth in the fragmented $40 billion deli market.
Zeta Global Holdings (ZETA)
Overview: Zeta Global Holdings Corp. operates an omnichannel data-driven cloud platform offering consumer intelligence and marketing automation software to enterprises worldwide, with a market cap of approximately $4.28 billion.
Operations: The company generates revenue primarily from its Internet Software & Services segment, amounting to $1.44 billion.
Estimated Discount To Fair Value: 37.8%
Zeta Global Holdings, trading at US$17.19, is significantly undervalued with a discounted cash flow value of US$27.63. The company has raised its revenue guidance for 2026 to between US$1.779 billion and US$1.792 billion, reflecting robust growth potential despite slower-than-20% annual revenue forecasts. Recent initiatives like joining the Open Semantic Interchange and launching Athena by Zeta™ enhance data interoperability and marketing efficiency, supporting Zeta's path toward profitability within three years with strong earnings growth expectations of 48.7% annually.
Summing It All Up
- Take a closer look at our Undervalued US Stocks Based On Cash Flows list of 143 companies by clicking here.
- Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
- Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Looking For Alternative Opportunities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
